These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 39235358)

  • 1. Dose Estimation Utility in a Population Pharmacokinetic Analysis of Inhaled Δ9-Tetrahydrocannabinol Cannabis Market Products in Occasional and Daily Users.
    Henthorn TK; Wang GS; Dooley G; Brooks-Russell A; Wrobel J; Limbacher S; Kosnett M
    Ther Drug Monit; 2024 Oct; 46(5):672-680. PubMed ID: 39235358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using Population Pharmacokinetic Modeling to Estimate Exposure to Δ9-Tetrahydrocannabinol in an Observational Study of Cannabis Smokers in Colorado.
    Sempio C; Bidwell LC; Hutchison K; Huestis MA; Klawitter J; Christians U; Henthorn TK
    Ther Drug Monit; 2021 Aug; 43(4):536-545. PubMed ID: 33656464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics model of THC used by pulmonary route in occasional cannabis smokers.
    Marsot A; Audebert C; Attolini L; Lacarelle B; Micallef J; Blin O
    J Pharmacol Toxicol Methods; 2017; 85():49-54. PubMed ID: 28167229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study.
    van der Pol P; Liebregts N; Brunt T; van Amsterdam J; de Graaf R; Korf DJ; van den Brink W; van Laar M
    Addiction; 2014 Jul; 109(7):1101-9. PubMed ID: 24628797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of smoked cannabis with high Δ(9)-tetrahydrocannabinol content: a kinetic model.
    Hunault CC; van Eijkeren JC; Mensinga TT; de Vries I; Leenders ME; Meulenbelt J
    Toxicol Appl Pharmacol; 2010 Aug; 246(3):148-53. PubMed ID: 20450927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic modeling of plasma Δ9-tetrahydrocannabinol and an active and inactive metabolite following controlled smoked cannabis administration.
    Sempio C; Huestis MA; Mikulich-Gilbertson SK; Klawitter J; Christians U; Henthorn TK
    Br J Clin Pharmacol; 2020 Mar; 86(3):611-619. PubMed ID: 31747464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simulated driving performance among daily and occasional cannabis users.
    Brooks-Russell A; Brown T; Friedman K; Wrobel J; Schwarz J; Dooley G; Ryall KA; Steinhart B; Amioka E; Milavetz G; Sam Wang G; Kosnett MJ
    Accid Anal Prev; 2021 Sep; 160():106326. PubMed ID: 34403895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Δ9-tetrahydrocannabinol (THC) is present in the body between smoking sessions in occasional non-daily cannabis users.
    Mørland J; Bramness JG
    Forensic Sci Int; 2020 Apr; 309():110188. PubMed ID: 32120192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint.
    Fabritius M; Chtioui H; Battistella G; Annoni JM; Dao K; Favrat B; Fornari E; Lauer E; Maeder P; Giroud C
    Anal Bioanal Chem; 2013 Dec; 405(30):9791-803. PubMed ID: 24202191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC.
    Karschner EL; Schwope DM; Schwilke EW; Goodwin RS; Kelly DL; Gorelick DA; Huestis MA
    Drug Alcohol Depend; 2012 Oct; 125(3):313-9. PubMed ID: 22464363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Naturalistic Administration of Cannabis Flower and Concentrates With Intoxication and Impairment.
    Bidwell LC; Ellingson JM; Karoly HC; YorkWilliams SL; Hitchcock LN; Tracy BL; Klawitter J; Sempio C; Bryan AD; Hutchison KE
    JAMA Psychiatry; 2020 Aug; 77(8):787-796. PubMed ID: 32520316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.
    Milman G; Bergamaschi MM; Lee D; Mendu DR; Barnes AJ; Vandrey R; Huestis MA
    Ther Drug Monit; 2014 Apr; 36(2):218-24. PubMed ID: 24067260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood cannabinoid molar metabolite ratios are superior to blood THC as an indicator of recent cannabis smoking.
    Kosnett MJ; Ma M; Dooley G; Wang GS; Friedman K; Brown T; Henthorn TK; Brooks-Russell A
    Clin Toxicol (Phila); 2023 May; 61(5):355-362. PubMed ID: 37293900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabis effects on driving lateral control with and without alcohol.
    Hartman RL; Brown TL; Milavetz G; Spurgin A; Pierce RS; Gorelick DA; Gaffney G; Huestis MA
    Drug Alcohol Depend; 2015 Sep; 154():25-37. PubMed ID: 26144593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC.
    Hunault CC; Mensinga TT; de Vries I; Kelholt-Dijkman HH; Hoek J; Kruidenier M; Leenders ME; Meulenbelt J
    Psychopharmacology (Berl); 2008 Dec; 201(2):171-81. PubMed ID: 18695931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Pharmacokinetic Profile of Smoked and Vaporized Cannabis in Human Blood and Oral Fluid.
    Spindle TR; Cone EJ; Schlienz NJ; Mitchell JM; Bigelow GE; Flegel R; Hayes E; Vandrey R
    J Anal Toxicol; 2019 May; 43(4):233-258. PubMed ID: 30615181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex differences in the acute effects of smoked cannabis: evidence from a human laboratory study of young adults.
    Matheson J; Sproule B; Di Ciano P; Fares A; Le Foll B; Mann RE; Brands B
    Psychopharmacology (Berl); 2020 Feb; 237(2):305-316. PubMed ID: 31637452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The minor cannabinoid cannabigerol (CBG) is a highly specific blood biomarker of recent cannabis smoking.
    Rague JM; Ma M; Dooley G; Wang GS; Friedman K; Henthorn TK; Brooks-Russell A; Kosnett MJ
    Clin Toxicol (Phila); 2023 May; 61(5):363-369. PubMed ID: 36939145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating the time of last cannabis use from plasma delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol concentrations.
    Huestis MA; Barnes A; Smith ML
    Clin Chem; 2005 Dec; 51(12):2289-95. PubMed ID: 16223887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable Delta-9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics After Cannabis Smoking in Regular Users.
    Liyanage M; Nikanjam M; Capparelli EV; Suhandynata RT; Fitzgerald RL; Marcotte TD; Grant I; Momper JD
    Ther Drug Monit; 2023 Oct; 45(5):689-696. PubMed ID: 37199428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.